182 related articles for article (PubMed ID: 25107702)
1. MCL-1 dependency of cisplatin-resistant cancer cells.
Michels J; Obrist F; Vitale I; Lissa D; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Castedo M; Kroemer G
Biochem Pharmacol; 2014 Nov; 92(1):55-61. PubMed ID: 25107702
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin resistance associated with PARP hyperactivation.
Michels J; Vitale I; Galluzzi L; Adam J; Olaussen KA; Kepp O; Senovilla L; Talhaoui I; Guegan J; Enot DP; Talbot M; Robin A; Girard P; Oréar C; Lissa D; Sukkurwala AQ; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Dessen P; Saparbaev M; Soria JC; Castedo M; Kroemer G
Cancer Res; 2013 Apr; 73(7):2271-80. PubMed ID: 23554447
[TBL] [Abstract][Full Text] [Related]
3. MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC.
Ma J; Zhao Z; Wu K; Xu Z; Liu K
Gene; 2016 Aug; 587(2):147-54. PubMed ID: 27138804
[TBL] [Abstract][Full Text] [Related]
4. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
5. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
[TBL] [Abstract][Full Text] [Related]
6. Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1.
Li Q; Zhan M; Chen W; Zhao B; Yang K; Yang J; Yi J; Huang Q; Mohan M; Hou Z; Wang J
Oncotarget; 2016 Mar; 7(9):10271-82. PubMed ID: 26848531
[TBL] [Abstract][Full Text] [Related]
7. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance.
Pyndiah S; Tanida S; Ahmed KM; Cassimere EK; Choe C; Sakamuro D
Sci Signal; 2011 Mar; 4(166):ra19. PubMed ID: 21447800
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
Zhang F; Shen M; Yang L; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Cancer Biol Ther; 2017 Aug; 18(8):606-615. PubMed ID: 28686074
[TBL] [Abstract][Full Text] [Related]
9. Mcl-1 suppresses abasic site repair following bile acid-induced hepatic cellular DNA damage.
Yu H; Zhang X; Liu R; Li H; Xiao X; Zhou Y; Wei C; Yang M; Liao M; Zhao J; Xia Z; Liao Q
Tumour Biol; 2017 Jul; 39(7):1010428317712102. PubMed ID: 28681695
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers.
Palve V; Mallick S; Ghaisas G; Kannan S; Teni T
PLoS One; 2014; 9(11):e111927. PubMed ID: 25409302
[TBL] [Abstract][Full Text] [Related]
11. Sensitizing thermochemotherapy with a PARP1-inhibitor.
Oei AL; Vriend LE; van Leeuwen CM; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJ; Crezee J; Kanaar R; Kok HP; Krawczyk PM; Franken NA
Oncotarget; 2017 Mar; 8(10):16303-16312. PubMed ID: 27557507
[TBL] [Abstract][Full Text] [Related]
12. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer.
Zhang W; Wan M; Ma L; Liu X; He J
Cell Biol Int; 2013 Jan; 37(1):47-53. PubMed ID: 23319321
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
Michels J; Vitale I; Senovilla L; Enot DP; Garcia P; Lissa D; Olaussen KA; Brenner C; Soria JC; Castedo M; Kroemer G
Cell Cycle; 2013 Mar; 12(6):877-83. PubMed ID: 23428903
[TBL] [Abstract][Full Text] [Related]
15. MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer.
Zhang R; Li Y; Dong X; Peng L; Nie X
Med Oncol; 2014 Dec; 31(12):347. PubMed ID: 25416050
[TBL] [Abstract][Full Text] [Related]
16. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
[TBL] [Abstract][Full Text] [Related]
17. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
18. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.
Brotin E; Meryet-Figuière M; Simonin K; Duval RE; Villedieu M; Leroy-Dudal J; Saison-Behmoaras E; Gauduchon P; Denoyelle C; Poulain L
Int J Cancer; 2010 Feb; 126(4):885-95. PubMed ID: 19634140
[TBL] [Abstract][Full Text] [Related]
19. Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells.
Toyozumi Y; Arima N; Izumaru S; Kato S; Morimatsu M; Nakashima T
Int J Oncol; 2004 Sep; 25(3):721-8. PubMed ID: 15289875
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
Kim J; Long KE; Tang K; Padanilam BJ
Kidney Int; 2012 Jul; 82(2):193-203. PubMed ID: 22437413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
